LDS/Medical Tests/Somatostatin, Plasma

Somatostatin, Plasma

Somatostatin is a cyclic peptide hormone produced in multiple sites, including pancreatic delta cells, the gastrointestinal tract, the hypothalamus, and other regions of the brain. It is primarily recognized for its inhibitory effects on both endocrine and gastrointestinal functions.

The hormone exists in two biologically active forms, somatostatin-14 and somatostatin-28, which act through five G-protein–coupled somatostatin receptors (SSTR1–SSTR5). When activated, these receptors reduce intracellular levels of cAMP and calcium, resulting in decreased secretion of hormones from target tissues. Beyond this inhibitory role, somatostatin also demonstrates anti-proliferative and cytostatic properties.

Abnormally high levels of somatostatin are most often associated with somatostatinoma, a rare neuroendocrine tumor typically arising in the pancreas or duodenum. These tumors release large amounts of somatostatin, leading to profound suppression of multiple endocrine and gastrointestinal processes. Clinical manifestations may include mild diabetes or glucose intolerance due to reduced insulin secretion, gallstone formation from impaired cholecystokinin activity and gallbladder contraction, and steatorrhea or diarrhea as a result of decreased pancreatic enzyme secretion.

Somatostatinomas may occur sporadically or in the setting of genetic syndromes such as multiple endocrine neoplasia type 1 (MEN1) or neurofibromatosis type 1 (NF1). The mainstay of treatment is surgical resection, although in cases where surgery is not feasible, somatostatin analogs such as octreotide or lanreotide are used to control hormone-related symptoms.

  • As an aid in the diagnosis and monitoring of neuroendocrine neoplasms (Carcinoid tumors, somatostatinoma)
  • Aid in the differential diagnosis of neuroendocrine tumor syndromes, multiple endocrine neoplasia, type I
  • Evaluation of unexplained hormone-related symptoms (e.g., acromegaly, malabsorption, secretory diarrhea)
  • Supportive diagnostic aid in secondary diabetes mellitus due to hormone imbalance

Increased in:

  • Somatostatinoma
  • Neuroendocrine neoplasms
  • Ectopic somatostatin secretion
  • Multiple endocrine neoplasia, type I

Decreased in:

  • Dysfunctional delta-cells of pancreas
  • Hypothalamic/pituitary dysfunction
  • Zollinger-Ellison syndrome

Normal (fasting state): 10-100 pg/mL

Immunoassay (typically radioimmunoassay or ELISA; mass spectrometry emerging in research).

Plasma, EDTA.

Stability

  • Ambient: 8 hrs
  • Refrigerated: 8 hrs
  • Frozen: 28 days
5-Hydroxyindoleacetic acid (5-HIAA), ACTH, Chromogranin A, CBC, comprehensive metabolic panel, gastrin, vitamin B12, folate, hereditary neuroendocrine tumor gene mutation panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login